Based on the outcome of the two software, it is not difficult to find many keywords that are related to the treatment of PD-1, including “PD-L1”, “pembrolizumab” and “nivolumab”, which again suggests that ICIs such as PD-1 is the mainstream immunotherapy for glioma. This evidence concerns the gene CD274 and glioma.